We’ve often written about companies that work with hospitals to develop owned-and-operated specialty pharmacies. Those pharmacies boast that they that are significantly better than independent
Walgreens….. its been good to know ya! That’s not saying that Walgreens is going away. To the contrary, it is the dawn of a new day
The FDA recently approved a new first-in-class tyrosine kinase 2 (Tyk2) inhibitor, ORAL therapy, Sotyktu (deucravacitinib) from Bristol Myers Squibb, for the treatment of adults
The FDA recently approved a new infused therapy, Xenpozyme (olipudase-alfa) from Genzyme , for pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare
The FDA recently approved a novel infused therapy, Spevigo (spesolimab-sbzo) from Boehringer Ingelheim), with an indication for the treatment of generalized pustular psoriasis (GPP) flares
The FDA recently approved the fourth biosimilar to Genentech’s Avastin, Vegzelma (bevacizumab-adcd) from Celltrion USA. Vegzelma is an infused therapy administered by a healthcare professional.
The FDA recently approved a novel infused therapy, Terlivaz (terlipressin) from Mallinckrodt, with an indication for hepatorenal syndrome (HRS) with rapid reduction in kidney function. There are
The FDA recently approved a BLA for Rolvedon (eflapegrastim-xnst) from Spectrum Pharmaceuticals. It has an indication to decrease the incidence of infection, as manifested by febrile
The FDA has just approved an oral suspension therapy, Relyvrio from Amylyx Pharmaceuticals, for ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease). Relyvrio joins a surprisingly
A few weeks ago, a press release from Shields Health announced that it had obtained accreditation from URAC…… not as a dispensing specialty pharmacy but,
